Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Berger and coworkers [8] showed that well-formed capsids can result if assembly follows "local rules", in which only subunits with the conformation dictated by adjacent subunits can bind to and ...

Lower capsid doses further facilitate successful manufacturing and reduce the cost of goods. “If you say to a patient with a devastating CNS disease, ‘There’s a therapeutic that could save ...

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 ...

AI-assisted AAV capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results ...

Bio-Rad Laboratories, Inc has introduced Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 ...